EUVIMEDEUVIMED entdecken
Crossref

Immunosuppression Minimization in Belatacept-Treated Kidney Transplant Recipients Guided by Combined Cell-Free DNA and Blood Gene Expression Monitoring

Thomas Vanhove, David Wojciechowski, Hannah Gilligan

Transplantation Proceedings · 2025

DOI: 10.1016/j.transproceed.2025.10.023 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Transplantation Proceedings, 2025. Verfasst von Thomas Vanhove und 2 weiteren Autor:innen. Beteiligte Einrichtung: Renal Division, Mass General Brigham, Harvard Medical School, Boston, Massachusetts; Department of Nephrology, Centre Hospitalier de Luxembourg, Luxe…. Hauptthemen laut MEDLINE: Abatacept, Kidney Transplantation, Immunosuppressive Agents, Cell-Free Nucleic Acids. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 19 Literaturangaben. Gefördert von: CareDx Inc, Eurofins Viracor BioPharma Services.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: This study examined whether the combined use of donor-derived cell-free DNA (cfDNA) and gene expression profile testing can facilitate immunosuppression minimization in belatacept-treated kidney transplant recipients. METHODS: Patients at least one year out from transplant with stable renal function, no history of rejection, negative donor-specific antibodies (DSA), urine protein/creatinine ratio 0.5 g/g. There were no results suggesting (sub)clinical rejection or any other safety signals for these patients throughout the remainder of follow-up. CONCLUSION: These novel immune monitoring tools can help identify patients in a likely state of immunologic quiescence, who may be eligible for reductions in immunosuppressive therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AbataceptKidney TransplantationImmunosuppressive AgentsCell-Free Nucleic AcidsGene Expression ProfilingHumansFemaleMaleMiddle AgedAdultGraft Rejection

Substanzen

AbataceptImmunosuppressive AgentsCell-Free Nucleic Acids

Autor:innen und Institutionen

  • Renal Division, Mass General Brigham, Harvard Medical School, Boston, Massachusetts; Department of Nephrology, Centre Hospitalier de Luxembourg, Luxembourg.
  • Department of Medicine, University of Texas Southwestern Medical Center, Dallas, Texas.
  • Renal Division, Mass General Brigham, Harvard Medical School, Boston, Massachusetts. Electronic address: HGILLIGAN@mgh.harvard.edu.

Förderung

  • CareDx Inc
  • Eurofins Viracor BioPharma Services

Zitieren

APA

Vanhove, T., Wojciechowski, D., & Gilligan, H. (2025). Immunosuppression Minimization in Belatacept-Treated Kidney Transplant Recipients Guided by Combined Cell-Free DNA and Blood Gene Expression Monitoring. Transplantation Proceedings. https://doi.org/10.1016/j.transproceed.2025.10.023

Vancouver

Vanhove T, Wojciechowski D, Gilligan H. Immunosuppression Minimization in Belatacept-Treated Kidney Transplant Recipients Guided by Combined Cell-Free DNA and Blood Gene Expression Monitoring. Transplantation Proceedings. 2025. doi:10.1016/j.transproceed.2025.10.023

BibTeX
@article{Vanhove2025,
  author = {Vanhove, Thomas and Wojciechowski, David and Gilligan, Hannah},
  title = {Immunosuppression Minimization in Belatacept-Treated Kidney Transplant Recipients Guided by Combined Cell-Free DNA and Blood Gene Expression Monitoring},
  journal = {Transplantation Proceedings},
  year = {2025},
  doi = {10.1016/j.transproceed.2025.10.023}
}
Kostenlos starten →